SLC22A1 rs2197296: What Your Genotype Means
The rs2197296 variant is a genetic change located within the SLC22A1 gene, which provides instructions for making the organic cation transporter 1 (OCT1) protein. This specific variant has been studied for its potential association with how individuals experience side effects when taking the medication metformin.
What each genotype means
Typical transporter activity
This genotype represents the most common form of the SLC22A1 gene at this location. Research into this variant is limited, and it is not currently used to guide clinical metformin dosing. Please discuss any concerns regarding your medication response or side effects with your healthcare provider.
This is the most frequent genotype observed in most global populations.
Typical transporter activity
Carrying one copy of the T allele at this position has not been definitively linked to significant changes in metformin transport or clinical outcomes. Current evidence is limited, and this genotype does not provide enough information to alter treatment plans. Always consult your clinician or pharmacist regarding your specific medication regimen.
This heterozygous genotype is found at varying frequencies across different ancestral groups.
Potential altered transporter profile
Some studies investigate whether variants in the SLC22A1 gene influence how metformin is processed in the liver, though evidence for this specific variant remains limited and inconsistent. This genotype is not a diagnostic tool and should not be used to make changes to your medication. Please consult your healthcare provider to discuss your individual response to metformin.
This genotype is less common than the CC or CT genotypes in most studied populations.
Understanding the rs2197296 Variant
The rs2197296 variant is a single nucleotide polymorphism (SNP) situated within the SLC22A1 gene. In genetics, an intronic variant like this one is located in a non-coding region of the gene, meaning it does not directly alter the sequence of amino acids that make up the final protein. Instead, such variants may influence how the gene is regulated, how much protein is produced, or how the gene is spliced. Because SLC22A1 is a highly polymorphic gene, researchers frequently study these variations to understand why people respond differently to certain medications. While rs2197296 is cataloged as an intronic variant, its presence is often investigated alongside other functional variants in the same gene cluster to determine if it serves as a marker for broader genetic patterns that affect drug transport in the liver.
The Role of the SLC22A1 Gene
The SLC22A1 gene encodes the organic cation transporter 1 (OCT1) protein. This protein acts as a gatekeeper on the surface of liver cells, facilitating the uptake of various substances, including endogenous amines and certain medications. Metformin, a common treatment for type 2 diabetes, relies on OCT1 for efficient transport into hepatocytes, where it exerts its primary glucose-lowering effects. When the function of OCT1 is reduced due to genetic variation, the amount of metformin entering the liver can be altered. This change in transport efficiency is the primary reason scientists study SLC22A1 variants. If the transporter is less active, it may lead to lower concentrations of the drug in the liver, potentially impacting both the therapeutic efficacy and the side-effect profile experienced by the patient.
Research and Evidence Strength
Current research into rs2197296 and other SLC22A1 variants is categorized as having limited evidence regarding clinical utility. While some studies have observed associations between SLC22A1 variants and metformin intolerance—specifically gastrointestinal side effects—these findings are not always consistent across different study populations. Factors such as study design, the specific population cohort, and the presence of other genetic modifiers can influence the results. For instance, some research suggests that individuals with multiple reduced-function alleles in the SLC22A1 gene may be more likely to experience metformin intolerance, but rs2197296 specifically is often studied as part of a larger set of markers. Because the evidence is currently limited and sometimes mixed, it is not used as a standard diagnostic tool in clinical practice to predict how a patient will react to metformin.
Clinical Considerations and Next Steps
It is important to understand that genetic variants like rs2197296 are only one piece of a very complex puzzle. Many factors, including diet, lifestyle, kidney function, and other medications, play a significant role in how a person responds to metformin. Because the evidence linking this specific SNP to clinical outcomes is limited, it should not be used to make independent decisions about your health or medication regimen. If you are concerned about side effects or the effectiveness of your treatment, the most important step is to consult with your healthcare provider or pharmacist. They can evaluate your specific clinical situation, review your symptoms, and determine if any adjustments to your therapy are necessary. Never change your medication dosage or stop taking a prescribed treatment based on genetic information without professional medical guidance.
How common is this variant?
The rs2197296 variant is commonly observed in cohorts of individuals with type 2 diabetes and polycystic ovary syndrome (PCOS), though specific allele frequencies vary significantly by ancestral background.
Frequently asked questions
Does having the rs2197296 variant mean I will have side effects from metformin?
No. Genetic associations are statistical, not predictive for individuals. Many people with this variant tolerate metformin well, and side effects can be caused by many factors unrelated to your genetics.
Should I get a genetic test for SLC22A1 before starting metformin?
Currently, testing for SLC22A1 variants is not standard clinical practice. Because the evidence is limited, doctors typically rely on clinical monitoring rather than genetic testing to manage metformin therapy.
Can I use this information to change my diabetes medication?
No. You should never change your medication or dosage based on genetic reports. Always discuss any concerns about your treatment plan with your doctor or pharmacist.
What should I do if I experience side effects while taking metformin?
If you experience side effects, contact your healthcare provider. They may suggest strategies such as taking the medication with food, adjusting the dose, or switching to a different formulation to improve your comfort.
Sources & further reading
Educational information only, last refreshed 9/25/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2197296?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SLC22A1
A variant associated with the occurrence of gastrointestinal side effects in metformin users.
This variant in the SLC22A1 gene is associated with altered transport and response to the drug metformin.
Also known as OCT1 p.Met420del, this loss-of-function deletion directly diminishes hepatic uptake and glycemic response to metformin in patients with type 2 diabetes.
This SNP is investigated alongside rs72552763 for its role in modulating glycemic response and HbA1c levels in diabetic patients treated with metformin.
A missense variant in OCT1 that impairs organic cation cellular uptake, altering clinical responsiveness and gastrointestinal tolerance to metformin.
A well-characterized loss-of-function variant (M420del) in the organic cation transporter 1 (OCT1) that reduces hepatic uptake of metformin and other basic drugs, modulating therapeutic efficacy and side effects.